CTLA4 and myocarditis: Pharmacovigilance data indicate a low incidence of myocarditis with immune checkpoint inhibitors (ICIs), ranging from 0.27% to 0.9%, with higher rates in combination therapy and anti-PD-1/anti-CTLA-4 therapy.